Repositorio Dspace

Unravelling the landscape of Cannabis craving pharmacological treatments: a PRISMA-guided review of evidence

Mostrar el registro sencillo del ítem

dc.contributor.author Cruz Preto, Mayra
dc.contributor.author Trevizan Kortas, Guilherme
dc.contributor.author Kanaan Blaas, Israel
dc.contributor.author Silva Lassi, Dangela Layne
dc.contributor.author Waisman Campos, Marcela
dc.contributor.author Torales, Julio César
dc.contributor.author Ventriglio, Antonio
dc.contributor.author de Azevedo-Marques Périco, Cintia
dc.contributor.author Guerra de Andrade, Arthur
dc.contributor.author Castaldelli-Maia, João Mauricio
dc.date.accessioned 2024-02-23T13:56:03Z
dc.date.available 2024-02-23T13:56:03Z
dc.date.issued 2023-07-21
dc.identifier.citation Preto MC, Kortas GT, Blaas IK, Lassi DLS, Waisman Campos M, Torales J, Ventriglio A, de Azevedo-Marques Périco C, de Andrade AG, Castaldelli-Maia JM. Unravelling the landscape of Cannabis craving pharmacological treatments: a PRISMA-guided review of evidence. Int Rev Psychiatry. 2023 Aug-Sep;35(5-6):434-449. doi: 10.1080/09540261.2023.2231540. es_ES
dc.identifier.uri https://doi.org/10.1080/09540261.2023.2231540
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/1010
dc.description.abstract Currently, few treatments are available for craving in general, and none of them have received approval for cannabis craving. The objective of this review is to evaluate existing studies analysing treatments for cannabis craving and explore novel treatment possibilities for these patients. The study followed PRISMA guidelines and conducted an extensive database search. Inclusion criteria included human randomised controlled trials examining drug effects on craving symptoms. Exclusion criteria involved studies unrelated to craving, non-pharmacological treatments, duplicates, and non-English/Spanish/Portuguese articles. Our included 22 studies that investigated a wide range of compounds used for cravings related to other drugs, as well as interventions based on healthcare professionals' empirical knowledge. The current pharmacological treatments largely involve off-label drug use and the utilisation of cannabinoid-based medications, such as combinations of THC and lofexidine, oxytocin, progesterone, and N-acetylcysteine. These emerging treatments show promise and have the potential to revolutionise current clinical practices, but further investigation is needed to establish their efficacy. In this context, it is essential to consider non-pharmacological interventions, such as psychotherapy and behavioural treatments. These approaches play a crucial role in complementing pharmacological interventions and addressing the complex nature of the disorder. es_ES
dc.language.iso eng es_ES
dc.publisher Informa Healthcare es_ES
dc.subject Cannabinoid Receptor Agonists es_ES
dc.subject Agonistas de Receptores de Cannabinoides es_ES
dc.subject Cannabis es_ES
dc.subject Craving es_ES
dc.subject Ansia es_ES
dc.subject Dronabinol es_ES
dc.subject Hallucinogens es_ES
dc.subject Alucinógenos es_ES
dc.subject Marijuana Abuse es_ES
dc.subject Abuso de Marihuana es_ES
dc.subject Off-Label Use es_ES
dc.subject Uso Fuera de lo Indicado es_ES
dc.title Unravelling the landscape of Cannabis craving pharmacological treatments: a PRISMA-guided review of evidence es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.description.fil Fil: Waisman Campos, Marcela. Fleni. Departamento de Neurología. Servicio de Neurología Cognitiva, Neuropsicología y Neuropsiquiatría; Argentina.
dc.relation.ispartofVOLUME 35
dc.relation.ispartofVOLUME
dc.relation.ispartofNUMBER 5-6
dc.relation.ispartofPAGINATION 434-449
dc.relation.ispartofCOUNTRY Reino Unido
dc.relation.ispartofCITY Londres
dc.relation.ispartofTITLE International review of psychiatry
dc.relation.ispartofISSN 1369-1627
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en DSpace


Listar

Mi cuenta

Estadísticas